All patients (n=149) | Patients receiving prophylaxis (n=101) | Patients receiving thiopurine monotherapy (n=77) | Patients receiving anti-TNF monotherapy (n=11) | Patients receiving combination therapy (n=13) | No prophylaxis (n=48) | |
---|---|---|---|---|---|---|
Gender | ||||||
Male | 61 (40.9%) | 41 (40.6%) | 33 (42.9%) | 4 (36.4%) | 6 (46.2%) | 20 (41.6%) |
Female | 88 (59.1%) | 60 (59.4%) | 44 (57.1%) | 7 (63.6%) | 7 (53.8%) | 28 (58.4%) |
Montreal age | ||||||
A1 (below 16 years) | 30 (20.1%) | 19 (18.8%) | 13 (16.9%) | 2 (18.2%) | 4 (30.8%) | 11 (22.9%) |
A2 (17–40 years) | 91 (61.1%) | 67 (66.3%) | 54 (70.1%) | 7 (63.6%) | 6 (46.2%) | 24 (50.0%) |
A3 (over 40 years) | 28 (18.8%) | 15 (14.9%) | 10 (13%) | 2 (18.2%) | 3 (23.1%) | 13 (27.1%) |
Montreal location | ||||||
L1 (ileal) | 27 (18.1%) | 18 (17.8%) | 14 (18.2%) | 2 (18.2%) | 2 (15.4%) | 9 (18.8%) |
L2 (colonic) | 19 (12.8%) | 8 (7.9%) | 5 (6.5%) | 1 (9.1%) | 2 (15.4%) | 11 (22.9%) |
L3 (ileocolonic) | 103 (69.1%) | 75 (74.3%) | 58 (75.3%) | 8 (72.8%) | 9 (69.2%) | 28 (58.3%) |
Montreal behaviour | ||||||
B1 (non-stricturing, non-penetrating) | 19 (12.8%) | 12 (11.9%) | 9 (11.7%) | 1 (9.1%) | 2 (15.4%) | 7 (14.6%) |
B2 (stricturing) | 90 (60.4%) | 101 (58.4%) | 46 (59.7%) | 5 (45.5%) | 8 (61.5) | 31 (64.6%) |
B3 (penetrating) | 40 (26.8%) | 30 (29.7%) | 22 (28.6%) | 5 (45.5%) | 3 (23.1%) | 10 (20.9%) |
Previous Crohn's resection | 53 (35.6%) | 36 (35.6%) | 23 (29.9%) | 6 (54.5%) | 7 (53.8) | 17 (35.4%) |
Smoking (at time of surgery) | 46 (30.9%) | 30 (29.7%) | 24 (31.2%) | 3 (27.3%) | 3 (23.1 | 16 (33.3%) |
Preoperative treatment | ||||||
No immunomodulator | 53 (34.9%) | 29 (28.7%) | 29 (37.7%) | 0 | 1 (7.7%) | 24 (50.0%) |
Thiopurine | 90 (60.4%) | 66 (65.3%) | 45 (58.4%) | 10 (90.9%) | 10 (76.9%) | 24 (50.0%) |
Methotrexate | 26 (17.4%) | 18 (17.8%) | 6 (7.8%) | 5 (45.5%) | 5 (38.5%) | 8 (16.7%) |
Anti-TNF-α | 49 (32.9%) | 34 (33.7%) | 18 (23.4%) | 9 (81.8%) | 7 (53.8%) | 15 (31.3%) |
TNF, tumour necrosis factor.